Clarithromycin for Safe and Cost-Effective Reduction of Cyclosporine Doses in Lung Allograft Recipients

Mark T. Knower, Kathy Labella-Walker, P. Michael McFadden, Stephen P. Kantrow, Vincent G. Valentine

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background. This study was done to analyze the economic effect of clarithromycin on the daily dosing of cyclosporine in lung transplantation. Methods. Nine consecutive patients (mean age ± SEM, 34.6 ± 5.2 years) had transplantation from June 1995 to June 1996. Median follow-up time was 649 days (range, 431 to 799 days). Preoperative diagnoses were cystic fibrosis (n = 4), idiopathic pulmonary fibrosis (n = 2), emphysema, bronchiectasis, and obliterative bronchiolitis. Median time from transplantation to addition of clarithromycin to a standard immunosuppressive regimen was 86 days (range, 14 to 181 days). Results. Baseline cyclosporine dose (9.9 ± 2.2 mg/kg/day) was reduced to 5.8 ± 1.0 mg/kg/day and 4.1 ± 0.8 mg/kg/day at 1 month and 1 year, respectively, after initiation of clarithromycin therapy. Estimated annual savings were $3,400 per patient. There was no increase in infection or rejection episodes. Conclusions. Clarithromycin safely reduced the dose and cost of cyclosporine in this series.

Original languageEnglish (US)
Pages (from-to)1087-1092
Number of pages6
JournalSouthern Medical Journal
Volume93
Issue number11
StatePublished - Nov 2000
Externally publishedYes

Fingerprint

Clarithromycin
Cyclosporine
Allografts
Costs and Cost Analysis
Lung
Transplantation
Idiopathic Pulmonary Fibrosis
Bronchiolitis
Bronchiectasis
Lung Transplantation
Emphysema
Immunosuppressive Agents
Cystic Fibrosis
Economics
Infection
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Knower, M. T., Labella-Walker, K., McFadden, P. M., Kantrow, S. P., & Valentine, V. G. (2000). Clarithromycin for Safe and Cost-Effective Reduction of Cyclosporine Doses in Lung Allograft Recipients. Southern Medical Journal, 93(11), 1087-1092.

Clarithromycin for Safe and Cost-Effective Reduction of Cyclosporine Doses in Lung Allograft Recipients. / Knower, Mark T.; Labella-Walker, Kathy; McFadden, P. Michael; Kantrow, Stephen P.; Valentine, Vincent G.

In: Southern Medical Journal, Vol. 93, No. 11, 11.2000, p. 1087-1092.

Research output: Contribution to journalArticle

Knower, MT, Labella-Walker, K, McFadden, PM, Kantrow, SP & Valentine, VG 2000, 'Clarithromycin for Safe and Cost-Effective Reduction of Cyclosporine Doses in Lung Allograft Recipients', Southern Medical Journal, vol. 93, no. 11, pp. 1087-1092.
Knower MT, Labella-Walker K, McFadden PM, Kantrow SP, Valentine VG. Clarithromycin for Safe and Cost-Effective Reduction of Cyclosporine Doses in Lung Allograft Recipients. Southern Medical Journal. 2000 Nov;93(11):1087-1092.
Knower, Mark T. ; Labella-Walker, Kathy ; McFadden, P. Michael ; Kantrow, Stephen P. ; Valentine, Vincent G. / Clarithromycin for Safe and Cost-Effective Reduction of Cyclosporine Doses in Lung Allograft Recipients. In: Southern Medical Journal. 2000 ; Vol. 93, No. 11. pp. 1087-1092.
@article{b3d44c4912994683bba24f3dd10b8050,
title = "Clarithromycin for Safe and Cost-Effective Reduction of Cyclosporine Doses in Lung Allograft Recipients",
abstract = "Background. This study was done to analyze the economic effect of clarithromycin on the daily dosing of cyclosporine in lung transplantation. Methods. Nine consecutive patients (mean age ± SEM, 34.6 ± 5.2 years) had transplantation from June 1995 to June 1996. Median follow-up time was 649 days (range, 431 to 799 days). Preoperative diagnoses were cystic fibrosis (n = 4), idiopathic pulmonary fibrosis (n = 2), emphysema, bronchiectasis, and obliterative bronchiolitis. Median time from transplantation to addition of clarithromycin to a standard immunosuppressive regimen was 86 days (range, 14 to 181 days). Results. Baseline cyclosporine dose (9.9 ± 2.2 mg/kg/day) was reduced to 5.8 ± 1.0 mg/kg/day and 4.1 ± 0.8 mg/kg/day at 1 month and 1 year, respectively, after initiation of clarithromycin therapy. Estimated annual savings were $3,400 per patient. There was no increase in infection or rejection episodes. Conclusions. Clarithromycin safely reduced the dose and cost of cyclosporine in this series.",
author = "Knower, {Mark T.} and Kathy Labella-Walker and McFadden, {P. Michael} and Kantrow, {Stephen P.} and Valentine, {Vincent G.}",
year = "2000",
month = "11",
language = "English (US)",
volume = "93",
pages = "1087--1092",
journal = "Southern Medical Journal",
issn = "0038-4348",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Clarithromycin for Safe and Cost-Effective Reduction of Cyclosporine Doses in Lung Allograft Recipients

AU - Knower, Mark T.

AU - Labella-Walker, Kathy

AU - McFadden, P. Michael

AU - Kantrow, Stephen P.

AU - Valentine, Vincent G.

PY - 2000/11

Y1 - 2000/11

N2 - Background. This study was done to analyze the economic effect of clarithromycin on the daily dosing of cyclosporine in lung transplantation. Methods. Nine consecutive patients (mean age ± SEM, 34.6 ± 5.2 years) had transplantation from June 1995 to June 1996. Median follow-up time was 649 days (range, 431 to 799 days). Preoperative diagnoses were cystic fibrosis (n = 4), idiopathic pulmonary fibrosis (n = 2), emphysema, bronchiectasis, and obliterative bronchiolitis. Median time from transplantation to addition of clarithromycin to a standard immunosuppressive regimen was 86 days (range, 14 to 181 days). Results. Baseline cyclosporine dose (9.9 ± 2.2 mg/kg/day) was reduced to 5.8 ± 1.0 mg/kg/day and 4.1 ± 0.8 mg/kg/day at 1 month and 1 year, respectively, after initiation of clarithromycin therapy. Estimated annual savings were $3,400 per patient. There was no increase in infection or rejection episodes. Conclusions. Clarithromycin safely reduced the dose and cost of cyclosporine in this series.

AB - Background. This study was done to analyze the economic effect of clarithromycin on the daily dosing of cyclosporine in lung transplantation. Methods. Nine consecutive patients (mean age ± SEM, 34.6 ± 5.2 years) had transplantation from June 1995 to June 1996. Median follow-up time was 649 days (range, 431 to 799 days). Preoperative diagnoses were cystic fibrosis (n = 4), idiopathic pulmonary fibrosis (n = 2), emphysema, bronchiectasis, and obliterative bronchiolitis. Median time from transplantation to addition of clarithromycin to a standard immunosuppressive regimen was 86 days (range, 14 to 181 days). Results. Baseline cyclosporine dose (9.9 ± 2.2 mg/kg/day) was reduced to 5.8 ± 1.0 mg/kg/day and 4.1 ± 0.8 mg/kg/day at 1 month and 1 year, respectively, after initiation of clarithromycin therapy. Estimated annual savings were $3,400 per patient. There was no increase in infection or rejection episodes. Conclusions. Clarithromycin safely reduced the dose and cost of cyclosporine in this series.

UR - http://www.scopus.com/inward/record.url?scp=0034321547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034321547&partnerID=8YFLogxK

M3 - Article

VL - 93

SP - 1087

EP - 1092

JO - Southern Medical Journal

JF - Southern Medical Journal

SN - 0038-4348

IS - 11

ER -